Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines ; volume:16 ; number:1 ; day:6 ; month:12 ; year:2018 ; pages:1-18 ; date:12.2018
BMC medicine ; 16, Heft 1 (6.12.2018), 1-18, 12.2018
- Creator
-
de Boer, Pieter T.
van Lier, Alies
de Melker, Hester
van Wijck, Albert J. M.
Wilschut, Jan C.
van Hoek, Albert Jan
Postma, Maarten J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-018-1213-5
- URN
-
urn:nbn:de:101:1-2019020601561050989593
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- de Boer, Pieter T.
- van Lier, Alies
- de Melker, Hester
- van Wijck, Albert J. M.
- Wilschut, Jan C.
- van Hoek, Albert Jan
- Postma, Maarten J.
- SpringerLink (Online service)
Other Objects (12)
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
Varicella zoster gastritis in an immunocompetent adult woman
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Herpes zoster and meningitis in an immunocompetent child: a case report
A rare case of disseminated cutaneous zoster in an immunocompetent patient
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Bilateral asymmetrical herpes-zoster with Ramsay hunt syndrome in an immunocompetent adult
Varicella-Zoster Virus Encephalitis in an Immunocompetent Adult with Disseminated Cutaneous Herpes Zoster after Testosterone Booster Supplements: Case Report
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
Varicella zoster gastritis in an immunocompetent adult woman
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Herpes zoster and meningitis in an immunocompetent child: a case report
A rare case of disseminated cutaneous zoster in an immunocompetent patient
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Bilateral asymmetrical herpes-zoster with Ramsay hunt syndrome in an immunocompetent adult
Varicella-Zoster Virus Encephalitis in an Immunocompetent Adult with Disseminated Cutaneous Herpes Zoster after Testosterone Booster Supplements: Case Report
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
Varicella zoster gastritis in an immunocompetent adult woman
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Herpes zoster and meningitis in an immunocompetent child: a case report
A rare case of disseminated cutaneous zoster in an immunocompetent patient
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Bilateral asymmetrical herpes-zoster with Ramsay hunt syndrome in an immunocompetent adult
Varicella-Zoster Virus Encephalitis in an Immunocompetent Adult with Disseminated Cutaneous Herpes Zoster after Testosterone Booster Supplements: Case Report
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia